Free Trial
NASDAQ:ETNB

89bio Q2 2023 Earnings Report

89bio logo
$10.11 +0.27 (+2.74%)
Closing price 06/2/2025 04:00 PM Eastern
Extended Trading
$9.94 -0.16 (-1.63%)
As of 06/2/2025 07:16 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

89bio EPS Results

Actual EPS
-$0.52
Consensus EPS
-$0.44
Beat/Miss
Missed by -$0.08
One Year Ago EPS
N/A

89bio Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

89bio Announcement Details

Quarter
Q2 2023
Time
Q2 2023 Earnings Release
Conference Call Date
Wednesday, August 9, 2023
Conference Call Time
7:00AM ET

Upcoming Earnings

89bio's Q2 2025 earnings is scheduled for Monday, August 4, 2025, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

89bio Earnings Headlines

Elon’s Parting Gift
White House to reset Social Security? President Trump's inner circle has a plan that could radically change how Social Security works. In fact, just days after taking office, President Trump signed Executive Order 14179 - giving his team new powers to permanently reset how many key federal agencies work. That reset is now ready to begin - and it's critical you start preparing your money immediately.
Is Now the Time to Buy Biotech Stocks?
See More 89bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like 89bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on 89bio and other key companies, straight to your email.

About 89bio

89bio (NASDAQ:ETNB), a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.

View 89bio Profile

More Earnings Resources from MarketBeat